Therapeutics to tackle Omicron outbreak

Vivek P Chavda; Eswara Naga Hanuma Kumar Ghali; Murali M Yallapu; Vasso Apostolopoulos

doi:10.2217/imt-2022-0064

Therapeutics to tackle Omicron outbreak

Immunotherapy. 2022 Aug;14(11):833-838. doi: 10.2217/imt-2022-0064. Epub 2022 Jun 8.

Authors

Vivek P Chavda¹, Eswara Naga Hanuma Kumar Ghali^{2

3}, Murali M Yallapu^{2

3}, Vasso Apostolopoulos^{4

5}

Affiliations

¹ Department of Pharmaceutics & Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad, Gujarat, 380008, India.
² Department of Immunology & Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
³ South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
⁴ Institute for Health & Sport, Victoria University, Melbourne, Victoria, 3030, Australia.
⁵ Immunology Program, Australian Institute for Musculoskeletal Science (AIMSS), Melbourne, Victoria, 3021, Australia.

Abstract

Tweetable abstract In this commentary, the authors have focused on the mutational impact of the Omicron variant on the current therapeutics to manage #COVID19.

Keywords: COVID-19; Omicron; SARS-CoV-2; convalescent plasma; monoclonal antibody; mutation.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

COVID-19* / epidemiology
Disease Outbreaks
Humans
Mutation / genetics
SARS-CoV-2

Supplementary concepts

SARS-CoV-2 variants

Grants and funding

SC1 GM139727/GM/NIGMS NIH HHS/United States